PRAS40, when dephosphorylated, inhibits mTOR signaling, consequently decreasing ribosomal transcription via affecting the activation of 4E-BP1 and P70S6k, both of which play roles in tumour angiogenesis [48,49]. The gene discussed is MTOR; the disease is neoplasm.